IMMY - Imprimis Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201612/31/201512/31/2014
Total Revenue19,9429,7161,660
Cost of Revenue9,8315,2061,093
Gross Profit10,1114,510567
Operating Expenses
Research Development739332237
Selling General and Administrative24,95119,00010,477
Non Recurring303303303
Others---
Total Operating Expenses---
Operating Income or Loss-15,882-14,822-10,147
Income from Continuing Operations
Total Other Income/Expenses Net-5423131
Earnings Before Interest and Taxes-16,424-14,791-10,118
Interest Expense2,7741,1081,108
Income Before Tax-19,198-15,899-10,118
Income Tax Expense-111--
Minority Interest---
Net Income From Continuing Ops-19,087-15,899-10,118
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-19,087-15,899-10,118
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-19,087-15,899-10,118